The Role of Timed Awakening in Treatment of Enuresis
A Randomized Clinical Trial to Investigate the Efficacy and Feasibility of Timed Awakening in the Treatment of Enuresis
1 other identifier
interventional
40
1 country
1
Brief Summary
The goal of this clinical trial is to evaluate the effectiveness of nightly timed awakening in the treatment of nocturnal enuresis in children aged 6-17. The main questions it aims to:
- Determine feasibility of nightly timed awakenings
- Determine the role, if any, of comorbidities on resolution of enuresis
- Determine incidence of daytime accidents
- Obtain patient and parental satisfaction scores Researchers will compare a control group to treatment groups to see if there is any impact on nocturnal enuresis. Participants will be woken up by parents in the middle of the night to use the restroom. In addition, participants will receive 30 minute psychotherapy sessions using telehealth.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 4, 2024
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedStudy Start
First participant enrolled
October 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
September 19, 2024
April 1, 2024
2 years
September 4, 2024
September 5, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean number of wet nights reported in electronic survey weekly for 12-weeks
All study participants will report bed wetting via redcap electronic survey 1x/week for a 12-week period.
Baseline to 12-weeks
Secondary Outcomes (5)
Mean change from baseline in the number of wet nights/week reported in electronic survey
Baseline to 12-weeks
Percentage of patients with increased number of wet nights at 24-week follow-up as reported in electronic survey.
24-weeks post-intervention
Mean number of nights reported weekly in electronic survey with timed awakening for 12-week period for intervention arm.
Baseline to 12-weeks
Mean number of daytime accidents/week at baseline, end of 12-weeks and 24-weeks follow-up.
Baseline to 24-week follow-up
Mean satisfaction score obtained from patient and parental satisfaction questionnaire.
Baseline to 12-weeks
Study Arms (2)
Control
NO INTERVENTIONStandard of care, which includes in-clinic urotherapy at evaluation and 30-minutes psychotherapy sessions (every 3 weeks).
Nightly Timed Awakening
EXPERIMENTALControl-arm therapy plus a nightly timed-awakening intervention.
Interventions
Patients in this arm will be awakened 1-hr after going to bed by their caregiver(s) to use the restroom and then returned to sleep. This awakening will occur every night.
Eligibility Criteria
You may qualify if:
- aged 6-17
- referred to the urology clinic for enuresis (Enuresis in our study is defined as nocturnal or diurnal enuresis (more than 1 bedwetting episode/week) for greater than 3 months)
You may not qualify if:
- Diagnosis of enuresis with comorbid diagnosis of diabetes mellitus (type 1 and 2), diabetes insipidus, chronic kidney disease, polyuria and/or polydipsia
- Structural urologic disease (evaluated via baseline imaging)
- Diagnosis of neurodevelopmental delays or conditions (i.e. celebral palsy, autism spectrum disorder) that hinders inability to follow age-appropriate instructions
- Not potty trained
- Improved or resolved enuresis for patients recently evaluated (within the past 6 months)
- Non-English speaking
- Patients currently on any over-active-bladder (OAB) medications (b3- agonists, antichloingerics) or alpha blockers for urinary symptoms (i.e. alfuzosin, tamsulosion, etc) or anti-diurectic medications for urinary symptoms (i.e.: desmopression (DDAVP))
- Patients currently using bed-wetting alarms
- Patients and families who are actively seeing Pediatric Clinical Urologic Psychologist.
- Inability or unwillingness of individual or legal guardian/representative to give written informed consent or participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Evalynn Vasquez, MD
Children's Hospital Los Angeles
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Staff/USC Faculty CWR
Study Record Dates
First Submitted
September 4, 2024
First Posted
September 19, 2024
Study Start
October 1, 2024
Primary Completion (Estimated)
October 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
September 19, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share